Johnson & Johnson's Q1 2010 earnings call highlighted robust performance amidst headwinds.  While the pharmaceutical segment faced challenges from generic competition and healthcare reform, the medical devices division showed strong operational growth.  Management emphasized the underlying strength of the businesses and the ability to offset these pressures, which suggests a positive outlook for the short-term, as they are seeing growth in other areas and have a stable cash position.
[1]
